Findings highlight APOE, BACE1, and CSF1R as key therapeutic targets as key therapeutic targets and identify compound 2a as a promising multi-target lead candidate for additional experimental validation in AD.
Abstract
Alzheimer’s disease (AD) is a complex neurodegenerative condition marked by amyloid-β accumulation, tau pathology, and neuroinflammation, while current single-target therapies largely provide symptomatic relief without effectively halting disease progression. Therefore, the rational design and synthesis of novel small molecules capable of simultaneously modulating multiple AD-related targets represent a promising therapeutic strategy. Based on this rationale, novel pyrazoline derivatives were synthesized and their therapeutic potential was evaluated using an integrative computational framework. AD-related genes were retrieved from GeneCards, CTD, and DisGeNET databases, and hub genes were identified through topological and centrality analyses, followed by functional enrichment analyses to explore their biological relevance. Molecular docking was used to evaluate the binding affinities of the synthesized compounds toward the identified hub targets, while 3D-QSAR modeling was used to predict their inhibitory potential. A total of 63 common genes were identified across the three databases, with APOE, BACE1, and CSF1R emerging as key hub genes. Enrichment analysis revealed their involvement in PI3K–Akt, mTOR, NF-κB, TNF, AMPK, and FoxO signaling pathways associated with amyloid processing, tau pathology, and neuroinflammation. Among the evaluated compounds, compound 2a exhibited the strongest binding affinities toward the hub targets along with favorable drug-likeness, pharmacokinetics, toxicity, and promising IC50 values (226–336 nM). The 3D-QSAR models showed high predictive reliability (R2 = 0.93–0.96; Q2 = 0.94–0.95). These findings highlight APOE, BACE1, and CSF1R as key therapeutic targets and identify compound 2a as a promising multi-target lead candidate for additional experimental validation in AD.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options offering only symptomatic relief. Natural fungal metabolites have recently gained attention for their neuroprotective potential. In this study, an extensive library of 18,349 fungal compounds was retrieved from the NPA...
Deepeesh Vijayan, K. Siva, Jayathraa Ramachandran et al.· Malaysian applied biology· 0 citations
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder predominantly affecting 47 million people worldwide. Dysregulation of BACE-1, the initiating enzyme in the amyloidogenic cascade, plays a pivotal role in AD pathogenesis. Conventional anticholinesterase inhibitors can only provide symptomat...
Pitam Ghosh, Ryena Dhir, Dinki Sharma et al.· Journal of Computational Bio...· 0 citations
Several of the identified multitarget phytochemicals are promising candidates for further experimental validation in AD therapy and supported by the literature, which shows that they can inhibit amyloid aggregation, tau phosphorylation, neuroinflammation, and cholinergic dysfunction.
Samuel Mesfin, N. Bloch, Abraham O. Samson· Frontiers in Drug Discovery· 0 citations
The findings of this study suggest that Hit1 could be a promising multi-target molecule capable of modulating cholinergic transmission, neuronal survival pathways, and oxidative stress in AD.
D. O. Onwu, R. Oria, Y. A. Adekunle et al.· Naunyn-Schmiedeberg's Archiv...· 0 citations
New derivatives based on benzofuran and pyrazole scaffolds designed and assessed for their antioxidant potential and acetylcholinesterase inhibitory activity provide further evidence for the potential of the designed compounds to behave as multi-target ligands with AChE inhibition and antioxidant properties that would...
Mohamed El Fadili, M. Er-rajy, S. Mujwar et al.· Frontiers in Chemistry· 0 citations
The rational design, synthesis, and biological evaluation of a new series of indole-piperazine based α-ketoamide moiety MD08 identify MD08 as a promising dual aggregation modulator for AD, warranting further preclinical investigation.
Bhanuranjan Das, Anurag T. K. Baidya, Deepak Chouhan et al.· European journal of medicina...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.